Understanding how to reduce inflammation after spinal cord injury
L-selectin shedding as a novel therapeutic strategy to mitigate acute secondary damage after spinal cord injury
This research explores how a common anti-inflammatory medicine might protect the spinal cord from further damage right after an injury.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Texas A&m University NIH-funded |
| Lab location | 1 site (College Station, United States) |
| Project ID | NIH-11135323 on NIH RePORTER |
What this research studies
When a spinal cord injury happens, inflammation can cause more damage to the surrounding tissues. This project looks at a specific protein on immune cells, called L-selectin, which plays a role in this harmful inflammation. Researchers are studying how an existing medicine, diclofenac, can reduce L-selectin activity, potentially limiting this secondary damage. The goal is to understand the exact ways this medicine helps to protect the spinal cord and improve recovery.
Who could benefit from this research
Good fit: This foundational research is relevant for individuals who have experienced an acute spinal cord injury.
Not a fit: Patients with chronic spinal cord injuries or other conditions not related to acute inflammation after injury may not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to new ways to protect the spinal cord immediately after an injury, potentially improving long-term recovery for patients.
How similar studies have performed: Previous findings suggest that diclofenac, which affects L-selectin, has shown promise in improving tissue protection and recovery after spinal cord injury.
Where this research is happening
College Station, United States
- Texas A&m University — College Station, United States (Active)
Researchers
- Principal investigator: Mccreedy, Dylan a. — Texas A&m University
- Study coordinator: Mccreedy, Dylan a.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.